Allergan Gets Over Pfizer Breakup Fast

by | Apr 7, 2016 5:17 pm | Pharmaceuticals

Allergan plc (NYSE: AGN) didn’t let any grass grow under its feet once the breakup with Pfizer Inc. (NYSE: PFE) was official, at 6:45 am ET on April 6th. At 7:30 pm ET the same day, Allergan announced it will partner with Heptares Therapeutics, a wholly owned subisidiary of Sosei Group Corporation (TSE: 4565), to get the exclusive global rights to a broad portfolio of drug candidates targeting major neurological disorders, including Alzheimer’s disease. Heptares receives $125 million upfront, and is eligible to receive contingent milestone payments of up to approximately $665 million associated with the successful Phase 1, 2 and 3 clinical development and laund of the first... Read More »